Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Cancer Of Unknown Primary Site.

G. Varadhachary, M. Raber
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cancer of unknown primary site was once viewed almost as a separate type of cancer, with the assumption that, regardless of the site of origin, the tumors in unknown primary cancers shared biologic properties, perhaps including rapid progression and dissemination, which contributed to their presentation. This view drove the conduct of phase 2 empirical trials over the past three decades, with the goal of developing standard chemotherapy regimens that would be effective in all patients with unknown primary cancer. The underlying assumption was that varia- tions in presentation would not have a substantial effect on therapeutic approaches or survival. Our view of unknown primary cancer has evolved as our understanding of cancer biology in general has matured to become much more personalized. Many people now believe that tumors in unknown primary cancer may retain the signa- ture of the putative primary origin and that extending the management of known cancers to subtypes of unknown primary cancer can contribute to advancements in therapies for this disease. Cancer of unknown primary site could even be seen as the epitome of personalized medicine, with individualized treatment driven by the mutational status of each patient. The biologic events that allow the primary site to remain obscure after the development of metastases have not yet been defined. Studies that have shown chromosomal abnormalities, microvessel density, aneuploidy, and overexpression of several genes suggest that these abnormalities are not unique to unknown pri- mary cancer. 7-11 With the use of the Sequenom MassARRAY platform, a study involving consecutive patients with unknown primary cancer showed a low rate of mutations (in 18% of patients). 12 No new, low-frequency mutations were found with the use of a panel of mutations involving the phosphatidylinositol 3-kinase
This paper references
10.1007/s10147-013-0583-0
Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
G. Varadhachary (2013)
10.1158/1078-0432.CCR-10-2599
Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary
G. Varadhachary (2011)
Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.
DeYoung Br (2000)
10.1016/S0002-9440(10)63090-8
Multi-platform, multi-site, microarray-based human tumor classification.
G. Bloom (2004)
10.6004/JNCCN.2011.0119
Carcinoma of unknown primary: focused evaluation.
G. Varadhachary (2011)
10.1097/00008469-200102000-00009
Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer
B. Rubin (2001)
10.1043/1543-2165(2008)132[384:AOITTD]2.0.CO;2
Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung.
J. Jagirdar (2008)
10.1158/0008-5472.CAN-04-3617
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
R. Tothill (2005)
10.1023/a:1017409423484
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP).
E. Briasoulis (2005)
10.1093/ANNONC/MDS357
Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling.
K. Oien (2012)
10.1200/JCO.2000.18.17.3101
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
E. Briasoulis (2000)
10.1023/A:1008369812295
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.
F. Greco (2000)
10.1002/hed.21566
Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: A prospective clinical trial
L. Rudmik (2011)
10.1200/JCO.2003.12.104
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
S. Culine (2003)
10.1200/JCO.2012.30.15_SUPPL.4131
Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system.
K. Hale (2012)
10.1200/JCO.2012.43.3755
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
J. Hainsworth (2013)
Angiogenesis in cancer of The New England Journal of Medicine Downloaded from nejm.org by RAUL
V Karavasilis (2014)
10.1016/J.EJCA.2007.06.023
Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
G. Pentheroudakis (2007)
Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study.
E. Briasoulis (1998)
10.1016/S0194-5998(00)70143-4
Tonsillectomy in diagnosis of the unknown primary tumor of the head and neck
D. A. Randall (2000)
10.1001/ARCHSURG.1983.01390060092027
Cancer: Principles and Practice of Oncology
G. Steele (1983)
10.1158/1078-0432.CCR-12-0920
Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier
S. Kerr (2012)
10.1200/JCO.2007.14.6969
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
H. Horlings (2008)
[Angiogenesis in cancer].
R. Pozner (2002)
Angiogenesis in cancer of The New England Journal of Medicine Downloaded from nejm.org by COUVREUR
V Karavasilis (2014)
10.1200/JCO.2011.29.15_SUPPL.10575
A second-generation microRNA-based assay for diagnosing tumor tissue origin.
R. Aharonov (2011)
10.1097/PAS.0b013e31828309c4
A Multicenter Study Directly Comparing the Diagnostic Accuracy of Gene Expression Profiling and Immunohistochemistry for Primary Site Identification in Metastatic Tumors
C. Handorf (2013)
10.1007/s10434-000-0411-4
Magnetic Resonance Imaging Facilitates Breast Conservation for Occult Breast Cancer
J. Olson (2000)
10.2147/VHRM.2006.2.3.213
Angiogenesis in Cancer
N. Nishida (2006)
10.1200/JCO.2002.04.019
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site.
S. Culine (2002)
10.1016/j.jmoldx.2012.10.001
Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors.
L. Weiss (2013)
10.1158/1078-0432.CCR-04-2236
Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm
J. L. Dennis (2005)
10.1056/NEJM199307223290407
Treatment of patients with cancer of an unknown primary site.
J. Hainsworth (1993)
10.1186/1471-2407-5-25
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
V. Karavasilis (2004)
10.1259/BJR/69059431
In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET.
U. Joshi (2004)
10.1093/ANNONC/MDI804
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP).
E. Briasoulis (2001)
10.1097/00000421-198602000-00020
Cancer : Principles and Practice of Oncology
V. Devita (1982)
10.1634/theoncologist.2010-0189
18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review.
A. Møller (2011)
Medicine Downloaded from nejm.org by RAUL RIBEIRO on August 25, 2014. For personal use only. No other uses without permission. Copyright © 2014 Massachusetts Medical Society
10.1016/J.YSUR.2011.09.017
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
T. Eberlein (2012)
10.1016/j.jmoldx.2010.11.001
Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens.
R. Pillai (2011)
10.7326/0003-4819-104-4-547
Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome.
F. Greco (1986)
10.1158/1078-0432.CCR-12-3030
New Strategies for Carcinoma of Unknown Primary: The Role of Tissue-of-Origin Molecular Profiling
G. Varadhachary (2013)
10.1634/theoncologist.2009-0328
Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.
F. Greco (2010)
10.1007/s00330-002-1674-x
Breast MR imaging in a patient with unilateral axillary lymphadenopathy and unknown primary malignancy
K. Schelfout (2002)
10.1016/S1470-2045(08)70151-7
Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.
G. Varadhachary (2008)
Br J Radiol
(2004)
10.1002/cncr.20687
The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor
Kyle E. Rusthoven (2004)
Mutation profiling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system National Comprehensive Cancer Network . Occult primary (cancer of unknown primary), version 1
Ks Hale (2012)
10.1053/j.seminoncol.2010.03.009
Cancer of unknown primary site.
G. Morris (2010)
10.1158/1078-0432.CCR-11-1446
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
M. Mao (2012)
10.1200/JCO.2000.18.3.632
Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.
J. Hainsworth (2000)
10.1002/path.2915
MicroRNA profiling for the identification of cancers with unknown primary tissue‐of‐origin
M. Ferracin (2011)
Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin.
N. Pavlidis (1995)
10.1002/(SICI)1097-0215(19970220)74:1<81::AID-IJC14>3.0.CO;2-L
Microvessel density in unknown primary tumors
H. Hillen (1997)
10.3760/CMA.J.ISSN.0366-6999
Breast magnetic resonance imaging in patients with occult breast carcinoma: evaluation on feasibility and correlation with histopathological findings.
H. Lu (2011)
10.1259/bjr/75018360
Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines.
M. B. Taylor (2012)
10.1093/jnci/djt099
Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
F. Greco (2013)



This paper is referenced by
10.1634/theoncologist.2018-0439
Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors.
P. Zhao (2019)
10.1016/j.jtho.2017.04.023
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.
I. Dagogo-Jack (2017)
10.1634/theoncologist.2020-0234
Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay
K. Raghav (2020)
10.1007/s12312-017-0232-z
Genomisch-histologische Analyse eines „cancer of unknown primary“
Stefan Gröschel (2017)
10.1634/theoncologist.2019-0798
Molecular Profiles of Brain and Pulmonary Metastatic Disease in Cancer of Unknown Primary.
B. Bakow (2020)
Hepatocellular carcinoma of unknown primary : a case report
Xuefeng Wang (2017)
10.1002/ijc.30176
Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival
Yifei Ma (2016)
Gene Expression Tests
(2014)
10.1007/s10735-015-9633-4
TGFβ modulates inflammatory cytokines and growth factors to create premetastatic microenvironment and stimulate lung metastasis
Y. Ye (2015)
10.1016/j.jtho.2018.03.019
Next-Generation Sequencing Assisted in Establishing the Diagnosis and Treatment for a Chinese Patient With Breast and Lung Multiple Primary Malignancies.
Chunqing Song (2018)
10.1093/jjco/hyw018
The possibility of clinical sequencing in the management of cancer.
T. Kou (2016)
10.1007/978-3-319-22581-4_10
Favorable Subsets Among Cancers of Unknown Primary
K. Raghav (2016)
10.1007/s12094-017-1807-y
SEOM clinical guideline on unknown primary cancer (2017)
F. Losa (2017)
10.1007/s12094-020-02296-9
Genomic profiling in oncology clinical practice
N. Rodríguez (2020)
10.1002/pon.4245
Patient‐oncologist alliance and psychosocial well‐being in Chinese society strongly affect cancer management adherence with cancer of unknown primary
Yifei Ma (2017)
10.1186/s12885-019-6155-6
Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait
Ryan W. Huey (2019)
10.1111/1346-8138.13828
Serum carcinoembryonic antigen specifically increases among various serum markers of adenocarcinoma in hypohidrosis or conditions related to hypohidrosis
M. Honma (2017)
10.2106/JBJS.16.00286
Quality of Life of Patients with Spinal Metastasis from Cancer of Unknown Primary Origin: A Longitudinal Study of Surgical Management Combined with Postoperative Radiation Therapy
Yifei Ma (2017)
Integrative Genomic Analy sis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles Graphical
F. Farshidfar (2017)
10.1101/151738
A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours
Jia-Ren Lin (2017)
10.1093/annonc/mdx545
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
A. Varghese (2017)
A review of metastatic cancer with unknown primary cancer
Laura Rodríguez (2018)
10.1098/rstb.2018.0224
Is cell migration a selectable trait in the natural evolution of cancer development?
A. Disanza (2019)
10.1016/j.ctrv.2016.11.014
Neck lymph node metastases from unknown primary.
A. Arosio (2017)
Gene expression pro fi ling identi fi es responsive patients with cancer of unknown primary treated with carboplatin , paclitaxel , and everolimus : NCCTG N 0871 ( alliance ) †
H. Yoon (2016)
10.3389/fgene.2019.01150
DNA Methylation Cancer Biomarkers: Translation to the Clinic
Warwick J. Locke (2019)
10.1007/s00259-016-3504-4
Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients
Yifei Ma (2016)
10.1016/j.ejca.2015.09.006
The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?
V. Prasad (2016)
10.1111/eva.13039
The role of host environment in cancer evolution
É. Solary (2020)
10.1093/annonc/mdv543
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
H. Yoon (2016)
10.1038/nrclinonc.2017.157
Cholangiocarcinoma — evolving concepts and therapeutic strategies
S. Rizvi (2018)
10.1007/978-3-319-39349-0_9
The Role of Proteomics in Personalized Medicine
D. Josić (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar